Gilead Sciences, Inc.

South Africa Urges Local Production of HIV Prevention Drug Lenacapavir

Gilead Sciences CFO Sells Ordinary Shares

Gilead Announces Q4 Earnings

GILD

SBIO

IBBQ

ProShare Advisors LLC increased its stake in Gilead Sciences, Inc. by 39.1% in Q4, acquiring 623,752 shares, bringing its total to 2,217,290 shares valued at $272.15 million. Other institutional investors also adjusted their holdings. Gilead's stock opened at $129.67, with a market cap of $160.99 billion. The company reported $2.03 EPS, exceeding estimates, and announced a quarterly dividend of $0.82 per share.

Market Beat

Gilead Sciences

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

VG Health

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

iShares Global Healthcare

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

VanEck Biotech ETF

iShares US Pharma

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD

Gilead Sciences is focusing on its HIV business while expanding its oncology and inflammation pipelines through recent acquisitions. Chief Commercial Officer Johanna Mercier highlighted strong growth in HIV, with key products like Yeztugo and Trodelvy driving performance. Recent acquisitions, including Arcellx and Tubulis, aim to enhance Gilead's capabilities in oncology and inflammation. The company anticipates significant market opportunities, particularly in multiple myeloma and ovarian cancer, while maintaining a strong position with no major loss of exclusivity expected until 2036.

Bank of America

Arcellx

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline

ABBV

Xilio Therapeutics, Inc. reported Q1 2026 revenue of $12.6M, up from $2.9M YoY, with a net loss of $(9.5) M, an improvement from $(13.3) M last year. The revenue increase was driven by collaborations with AbbVie and Gilead, while R&D expenses rose by $11.6M. The company expects to fund operations into early 2028 with current cash and potential Series C warrant exercises. Clinical trials for vilastobart and efarindodekin alfa are ongoing, with a milestone achieved in Q2 2026.

TradingView

Abbvie

Xilio Therapeutics

Xilio Therapeutics, Inc. 1Q 2026: Revenue $12.6M, EPS $(0.58) — 10-Q Summary

Today's market saw the tech sector decline, with Microsoft down 1.11% and Google down 2.01%, amid concerns over high valuations and regulatory scrutiny. In contrast, healthcare stocks thrived, led by Eli Lilly's 4.05% rise and Gilead Sciences' 2.62% increase, driven by positive clinical results. Consumer cyclicals struggled, with Tesla down 2.37% and Procter & Gamble down 2.03%. Investors are advised to reassess tech holdings while considering opportunities in healthcare and financial sectors for stability and growth.

Investinglive

Eli Lilly

Defiance Daily Target 2X Long LLY ETF

Microsoft

Alphabet

Tesla

Procter & Gamble

NVIDIA

Visa

JPMorgan Chase

Alphabet - C

NVIDIA Corporation

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

tech sector falters while healthcare stocks soar: dissecting today's market movements

Gilead Sciences (GILD) shares fell ~2% in after-hours trading despite Q1 results exceeding expectations. The company revised its 2026 non-GAAP EPS guidance to a loss of ($1.05)-($1.65), down from a prior estimate of $8.45-$8.85, due to $11.5B in IPR&D charges and financing costs. Gilead projects full-year product sales of $30B-$30.4B, aided by a 10% increase in HIV sales and significant growth in its breast cancer treatment, Trodelvy. As of March 31, Gilead's cash and equivalents stood at $8.6B, down from $10.6B at the end of 2025.

Gilead slips despite Q1 beats as it now expects 2026 loss per share

Gilead Sciences posted better-than-anticipated earnings for the first quarter. Shares fell anyway.

Gilead earnings show HIV drugs continue to shine. Why the guidance cut?